
REFERENCES

REFERENCES

Agar W, Hull D, Kaplan M, **Pletka** G (1979).

Acute cardiopulmonary, decompensation and complement activation during hemodialysis.

Ann Int Med, 90: 792-3.

Aljam P, Brid E, Ward MK, Feest G, Walker W, Tanboga H, Sussman M and Kerrdn S (1978).

Haemodialysis induced leucopenia and activation of complement: effect of different membranes.

Proc Eur Dial Transpl Assoc, 15: 144.

Assenat H, Calemard E, Charra B, Laurent G, Terrat C and Vanel T (1980).

Hemodialysis, carpel tunnel syndrome and amyloid substance.

Nouv Presse Med, 9 (24): 1715.

Atkins E (1960).

The pathogenesis of fever.

Physiol Rev, 40: 580-646.

Banilacqua P, Pober S, Majeau R, Cotran S and Gimbrone A (1985).

Interleukin-1 induces biosynthesis and cell surface expression of procoagulant activity on human vascular endothelial cells.

J Exp Med, 160: 618-23.

Bardin T, Zingiaff J, Benoit J, Kuntz D and Drueke T (1987).

Amyloidosis in hemodialysis patients.

Press Med, 16 (18): 907-10.

Barnes R, Hart C, Alexander L and Steen S (1983).

Immunological evaluation of renal transplant patients: Changes of B2-Microglobulin, **immunoglobulin** and complement component during graft rejection.

J Clin Lab Immunol, 12: 17-22.

Benz R (1984).

Carpal tunnel syndrom in CAPD: comparision with haemodialysis population
Am J Kidney Dis, 4: A2.

Beorchia S, Vincent C and Revillard P (1981).

Elevation of serum **B2-Microglobulin** in liver diseases.

Clin Chem Acta, 109: 245-55.

Berggard B, Bjorck L, Cigen R and Logdberg L (1980).

B2-Microglobulin

Scand J **Clin LabInvest**, 40 (suppl 154): 13-25.

Bernard M, Vyskocil A and **Lauwerys** P (1981).

Determination of B2-Microglobulin in human urine and serum by latex immunoassay.

Clin Chem 27: 832-7.

Bernick J, Port K and Favero S (1981).

In vivo studies of dialysis related endotoxemia and bacteraemia.

Nephron 27 307-319.

Beutler B and Cerami A (1987).

More than a tumor necrosis factor.

N Engl J Med, 316: 379-85.

Bingel M, Lonnemann G, Shaldon S, Koch M and Dinarello A (1986).

Human **interleukin-1** production during haemodialysis.

Nephron, 43: 161-3.

Bingel M, Lonnemann G, Koch M, Dinarello A and Shaldon S (1987).

Human **interleukin-1** production is enhanced by sodium acetate.

Lancet, I: 14-6.

Bischel D, Scoles G and Mohler G (1975).

Evidence for pulmonary microembolization during haemodialysis.

Chest, 67: 335.

Bixler J, Nelsen M and Bluemle W (1968).

The development of a difiltration system for blood purification.

Trans Am Soc Artif Intern Organs, 14: 99.

Bjerrum W, Bjerrum J and Borregaard N (1987).

B2-Microglobulin in neutrophils.

An intragranular Protein J **Immunol**, 138: 3931-7.

Blumenstein M, **Ziegler-Heitbrock L**, Schiller B, Schmidt B, Ward R and Gurland (1989).

Activation of mononuclear cells by adequate extracts from hollow fiber haemodialysis.

Nephrol Dial Transplant,4: 569-74.

Bogaert A, Vanholder R and Ringoir S (1987).

Influence of reuse of dialysers on the intradialytic evaluation of serum B2-Microglobulin.

445.

Brubaker L and **Nolph K** (1971).

Mechanism of recovery from neutropenia induced by haemodialysis.

Blood 38: 623-31.

Casey T, Stone J, Diraimondo R, Brantly D, **Diraimondo V**, Gorevic D and Page L (1986).

Tumoural **amyloidosis** of bone of B2-Microglobulin origin in association with long-term hemodialysis : A new type of amyloid disease.

Hum Pathol, 17: 731-8.

Cavaillon M, Fitting C and **Haeffner-Cavaillon** N (1990).

Recombinant **C5a** enhances **interleukin-1** and tumor necrosing factor release by **lipopolysaccharides** stimulated monocytes and macrophages.

Eur J Immunol 20: 253-7.

Chanard J, Levaud S and Toupance 0 (1986).

carpel tunnel syndrom and type of dialysis membrane used in patient undergoing long term hemodialysis.

Arthritis Rheum, 29: 1170-1.

Chenoweth E (1984).

Complement activation during hemodialysis clinical observation, proposed mechanisms, and theoretical **implicatios**.

Arif Organs, 8: 281-7.

Chenoweth E, Chenung K and Henderson W (1983).

Anaphylatoxin formation during hemodialysis: Effect of different dialyzer membranes.

Kidney INT, 24: 763-9.

Cheung K, Winter M, Chenoweth E and Henderson W (1986).

Cardiopulmonary effects of **cuprophane-activated** plasma in the swine.

Kidney **Int**, 29: 799-806.

Compistol M, Molina R, Bernard B and Rodriquez R (1993).

Synthesis of beta2-Microglobulin in lymphocyte culture: Role of hemodialysis, dialysis membranes, dialysis-amyloidosis, and **lymphokines**.

American journal of kidney diseases, 22 (5): 691-9.

Connors H, Shirahama T, Skinner M, Fenves A and Cohen S (1985).

In vitro formation of amyloid fibrils from intact B2-Microglobulin.

Biochem Biophys Res Commun, 131: 1063-8.

Craddock R, Fehr J, Brigham L, Kronenberg S and Jacob S (1977).

Complement and leucocyte-mediated pulmonary dysfunction in haemodialysis.

N Engl J Med 296: 770-4.

Craddock R, Fehr J, Dalmaso P, Brigham L and Jacob S (1979).

Haemodialysis leucopenia-pulmonary vascular leucostasis resulting from Complement activation by dialyzer cellophane membranes.

J Clin Invest 59: 879-88.

Craig C and Konigsberg W (1961).

Dialysis studies :- Modification of pore size and shape in cellophane membranes.

J Phys Chem, 65: 116.

Creswell P, Springer T, **Strominger** L, Turner J, Grey M and Kubo T (1974).
Immunological identity of the small subunit of **HLA** antigens and B2-Microglobulin and its turnover on the cell membrane.
Proc Natl Acad Sci, 71: 2123-207.

Delmez A, Hoffman B, Sicard A, Goldberg P and Harter R (1982).
Peripheral nerve entrapment syndromes in chronic hemodialysis patients.
Nephron, 30: 118-23.

Dinarello A (1983).
The biology of interleukin-1 and its relevance to hemodialysis.
Blood purification, 1: 197-224.

Dinarello A (1984).
Interleukin-1 and pathogenesis of the acute phase response.
N Engl J Med, 311: 1413-8.

Dinarello A (1985).
An update on human **interleukin-1** from molecular biology to clinical relevance.
J Clin Immunol, 5: 287-98.

Dinarello A (1987).
The biology of **interleukin-1** and comparison to tumor necrosis factor.
Immunol Lett, 16: 227-32.

Dinarello A (1988).

Biology of **interleukin-1**.

Faseb J, 2: 108-15.

Dinarello A (1989).

Interleukin-1 and other growth factors in: Kelley N, Harris D, Sledge B. Text book of rheumatology (3rd ed).

London, Montreal, Tokyo W.B. Saunders Co., 17:285-96.

Diraimondo R and Stone J (1987).

A **B2-Microglobulin** amyloidosis.

Int J Art Organs, 10(5): 281-5.

Donati D, Degiannis D, Homer L, Raska K and Raskova J (1991).

Interleukin-1 kinetics in hemodialysis.

Asaio Transactions, 37(3): M391-2.

Drukker W, Parsons M and Maher F (1983).

Replacement of renal function by dialysis.

Lyman Dj. membrane, 79-104.

Eastgate A, Symons A, Wood C, **Grinlinton** M, Digiovine S and Duff W (1988).

Correlation of plasma **interleukin-1** levels with disease activity in rheumatoid arthritis.

Lancet, 24: 706-9.

Emery P, Williamson J, Mackay R (1987).

Role of **cytokines** in rheumatological inflammation in : Cruse M, Lewis E.

Concepts immuopath.

Paris, London, Basel. Karegr, 171-99.

Evrin E, Peterson A and Wide L et al (1971).

Radioimmunoassay of B2-microglobulin in human biological.

Fluids Scand J Clin Lab Invest, 28: 439-43.

Falk W, Crammer H and Mannel N (1987).

A new assay for **interleukin-1 B**.

J Immunol methods, 99: 47.

Falkenhagen D, Thomaneck U and Brown S (1989).

Correlation of complement activation **cytokine** liberation & B2Min the use of various dialysis membranes.

Zurol Nephrol Oct, 82(10): 41-50.

Falkenhagen D, Bosch T, Brown S, Schmidt B, Holtz M, Baurmeister U, Gurland J and **Klinkmann** H (1987).

clinical study on different cellulosic dialysis membranes.

Nephrol Dial transplant, 2: 537-45.

Fearon T and Austen F (1980).

The alternative pathway of complement a system for host resistance to microbial infection.

N Engl J Med, 303: 259-63.

Ferrua B, Vincent C and Revillard P (1980).

A sandwich method of enzyme immunoassay, assay for human B2-**Microglobulin** compared with radio immunoassay.

J Immunol methods, 36: 149-58.

Floego J, Granolleras C and Bingel M (1987).

B2-Microglobulin kinetics during hemodialysis and hemofiltration.

Nephrol Dial Transplant, 1: 223-8.

Floege J, Bartsch A, Schulze M, Shaldon S, Koch M and Smeby C (1991).

Clearance and synthesis rates of B2-microglobulin in patient undergoing hemodialysis and in normal subjects.

Journal of laboratory & Clinical medicine, 118(2): 153-65.

Floego J, Granolleras C, Deschodt G, Heck M, Baudin G, Branger B, Tournier O, **Reinhardt** B, Eisenbach M, Smeby C and Shaldon S (1989).

High synthetic versus cellulosic membranes for **B2-Microglobulin** removal during hemodialysis.

Nephrol Dial Transplant, 4: 653-7.

Forman T (1983).

Serum B2-microglobulin as an indicator of Neoplasia.

J Clin Immunoassay, 6: 228-33.

Forman D, Finn W and Mandel S (1983).

Comparison of an enzyme immunoassay for serum B2-Microglobulin (B2-M) with a radio immunoassay technique.

Clin Chem, 29: 1245.

Gejyo F, Yamada T, Odani S, Hanma N, Saito H, Nakagawa Y and **Suzuki** Y (1986).

Beta2-Microglobulin : a new form of amyloid protein associated with chronic hemodialysis.

Kidney Int, 30: 385-90.

Gejyo F, Yamada T, Odani S, Nakagawa Y, **Arakawa** M, Kunieomo T, Kataoka H, Suzuki M, Hirasama Y, Shirahama T, Cohen S and Schmid K (1985).

A new form of amyloid protein associated with chronic haemodialysis identified as B2-Microglobulin.

Biochem Res Comm, 129: 702-6.

Gery I and **Waksman** H (1972).

Potentiation of the **T-lymphocyte** response to mitogens II. The cellular source of potentiating mediator (s).

J exp Med, 136: 143-55.

Glenner G (1980).

Amyloid deposits and amyloidosis. The **B-fibrilloses** 1.

N Engl J Med, 302: 1283-92.

Goldman M, Lietaer N, Lambert P, Thayse C and Vanherweghem J (1987).

Complement activation and leucopenia on cellulosic haemodialyzers: influence of the membrane area and role of hydroxyl moieties.

Life support systems, 5: 317-22.

Goodman G, Chenoweth E and Wiegler O (1982).

Induction of **interleukin-1** secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface **C5a** receptors.

J Exp Med, 1156: 912-7.

Gotch A, Sargent A, Teisinger L, Jones O and Lipps J (1971).

The hollow fibre artificial kidney.

Proc Eur Dial Transpl Assoc, 8: 568.

Haag-Weber M, Mai B, Deppisch L and Horl H (1994).

Studies of biocompatibility of different **dialyzer** membranes: Role of complement system, intracellular calcium and inositol-triphosphate.

Clinical Nephrology 41 (4): 245-51.

Hakim M, Fearon T and Lazarus M (1984).

Biocompatibility of dialysis membranes : Effect of chronic complement activation.

Kidney Int, 26: 194-200.

Hampl H, Lobeck H, Bartel-Schwarze S, Stein H, **Eulitz** M and Linke R (1987).

Clinical, morphological, biochemical and immuno-histochemical aspects of dialysis associated **amyloidosis**.

Trans Am Soc Artif Intern Organs, 33: 250-9.

Hannum H, Wilcox J, Arend P, Josline G, Dripps J, Heimdal L, Mines G, Sommer A, Ersenberg P and Thompson C (1990).

Interleukin-1 receptor antagonist activity of human **interleukin-1** inhibitor.

Nature, 343: 336-40.

Hauglustaine D, Weasr M, Michielsen P, Goebeis J and Vandeputte M (1986).

Haemodialysis membranes, serum **beta-2-microglobulin** and dialysis amyloidosis.

Lancet, 1: 1211.

Hellsing K and Enstrom H (1977).

Pre-treatment of serum samples for **immuno-nephelometric** analysis by precipitation with polyethylene.

Glycol Scand J Clin Lab Invest, 37: 529-36.

Henderson W, Koch M and Dinarello A (1983).

Haemodilysis hypotension :The **interleukin** hypothesis.

Blood **Purif**, 1: 3-8.

Hoekman K, Nieuwkoop J and Willemze R (1985).

The significance of **B2-Microglobulin** in clinical medicine.

Neth J Med, 28: 551-7.

Horl H, Riegel W, **Schollmeyer** P, **Rautenberg** W and Neumann S (1986).

Different complement and granulocyte activation in patient dialysed with PMMA dialysers.

Clin Nephrol, 25: 304-7.

Hosokawa S and Yoshida O (1991).

Removal of silicon, aluminum, and beta **2-Microglobulin** in chronic haemodialysis patients.

International Urology & Nephrology, 23(3): 281-4.

Indeglia A, Shea A, Forstrom R and Bernstein F (1968).

Influence of mechanical factors on erythrocyte sublethal damage.

Trans Ant Soc Artif Intern Organs, 14: 264.

Ivanovich P, Chenoweth E and Schmidt R (1983).

Symptoms and activation of granulocytes and complement with two dialysis membranes.

Kidney Int, 24: 758-63.

Jorstad S, Smeby C, Balstad T and Wideroe E (1988).

Removal generation and adsorption of beta2-Microglobulin during hemofiltration with five different membranes.

Blood Purif, 6: 96-105.

Kaplow S and Goffinet A (1968).

Profound neutropenia during the early phase of haemodialysis.

Jama, 203: 1135-1137.

Karlsson A, Groth T, Sege K, Wibell L and Peterson A (1980).

Turnover in humans of B2-Microglobulin the constant chain of HLA antigen.

Eur J Clin Invest, 10: 293-300.

Kaye J, Gillis S and Mizel B (1984).

Growth of a cloned helper T-cell line induced by a monoclonal antibody specific for the antigen receptor: **interleukin-1** is required for expression of receptors for **interleukin-2**.

Immunol, 133: 1339-45.

Kazatchkine D, Fearon T and Austen F (1979).

Human alternative complement pathway: Membrane-associated sialic acid regulates, The competition between B, and B 1 H for cell bound C3b.

J Immunol, 122: 75-81.

Knudsen J, Shaldon S and Koch M (1990).

Haemodialysis-related induction of B2M synthesis & release by mononuclear phagocytes.

Int J Artif Organs 13: 73-6.

Kostic S, Djordjevic V, Lecic N and Stefanovic V (1985).

Serum **B2-Microglobulin** in patients on maintenance hemodialysis. The effect of dialysis membrane.

Kidney Int, 28: 388

Kurz P, Kohler H, Meuer S, Hutteroth T, Meyer M and Buschenfelde H (1986).

Impaired cellular immune responses in chronic renal failure : Evidence for T-cell defect.

Kidney Int, 29: 1209-14.

Law K, Lichtenberg A and Levine P (1980).

Covalent binding and hemolytic activity of complement proteins : In activation by amines.

Proc Natl Acad Sci USA 77: 7194-8.

Lepe-Zuniga B and Grey I (1984).

Production of intracellular and extracellular **interleukin-1 (IL-1)** by human monocytes.

Clin Immunol Immunopathol, 31: 222.

Lesso H (1988).

Basic components of the immune system.

Medicine Int, 56: 2308-12.

Lindsay M (1980).

Variable heparine requirments during haemodialysis.

Asaio J, 3: 81.

Lindsay M, Prentice M, Davidson F, Burton A and Nicol P (1972).

Haemostatic changes during dialysis associated with thrombus formation on dialysis membranes.

Br Med J, 4: 545.

Lipsky E, Thompson A, Rosenwvasser J, and Dinarello A (1983).

The role of **interleukin-1** in human B-cell activation: inhibition of B-cell proliferation and the generation of **immunoglobulin** secreting cells by an antibody against human leucocytic pyrogen.

J Immunol, 130: 2709-14.

Lonnmann G, Koch M, Shaldon S and Dinarello A (1986).

Detection of endotoxin-like **interleukin-1** inducing activity during in vitro dialysis (Abstract).

Blood Purifecation, 4: 207-8:

Lonnmann G, Koch M, Shaldon S and Dinarello A (1987).

Induction of **interleukin-1** from human monocytes adhering to haemodialysis membranes (HD) (Abstract).

Kidney **Int**, 31: 238.

Lonnmann G, Bingel M, Floege J, Koch M, Shaldon S and Dinarello A (1988).

Detection of endotoxin-like **interleukin-1** inducing activity during in vitro dialysis

Kidney Int, 33: 29-35.

Lortan E, Kiepiela P, Hoosen M, Coovadia M and Seeda K (1982).

Suppressor cells assayed by numerical and functional tests in chronic renal failure.

Kidney **Int**, 22: 192-7.

Luger A, Kovarik J, Stummvoll H and Luger A (1987).

Cyto membrane interaction in hemodialysis leads to increased **cytokines** production.

Kidney **Int**, 32: 84-8.

Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello A and Swenson K (1986).

Affinity purified human **interleukin-1** is cytotoxic to isolated islets of langerhans.

Diabetologia, 29: 63-7.

Man K, Terlain B, Paris J, Werner G, Sausse A and **Funck-Bretano L** (1973).
 An approach to middle molecular identification in artificial kidney dialysis , with
 reference to neuropathy prevention.
 Trans Am Soc Artif Intern Organs, 19: 320.

March J, Mosley B and Larsen A (1985).
 Clothing sequence and expression of two distinct human interleukin-1
 complementary.
Dnas Nature, 315: 641-6.

Marshal W, Ahearn J, Nothum J, Esterly J, Nolph D and Maher F (1974).
 Adherence of blood components to dialyzer membranes; morphological studies.
 Nephron, 12: 157.

Mccarthy T, Williams W and Johson J (1994).
 Serum **beta-2-Microglobulin** concentration in dialysis patients: importance of
 intrinsic renal function.
 Journal of labretory & Clinical medicine, 123 (4): 495-505.

Meltzer H, Gutfreund K, Kulshrestha K and Stake M (1968).
 Optimized cellulose membranes foe artificial kidney dialysis applications.
 Trans Am Soc Intern Organs, 14: 12.

Messner P (1984).
B2-Microglobulin : An old molecule assumes a new look.
 J Lab Clin Med, 104 (2): 141-5.

Mrowka H and **Schiff** H (1993).

Comparative evaluation of B2-Microglobulin removal by different hemodialysis membranes: A six year follow up.

Nephron, 63: 368-9.

Muller-Eberhard J and Schrieber D (1980).

Molecular biology and chemistry of the alternative pathway of complement.

Adv **Immuno**, 29: 1-53.

Ogawa H, Saito A, Hirabayashi N and Hara K (1987).

Amyloid deposition in systemic organs in long term hemodialysis patients.

Clin Nephrol, 28 (4): 199-204.

Okusawa S, Dinarello A, Yancey B, Enders S, Lawley J, Franck M, Burke F and **Gelfrand** A (1987).

C5a induction of human **interleukin-1** synergistic effect with endotoxin or interferon.

J **Immunol**, 139: 2635-40.

Oppenheim J and Gery I (1982).

Interleukin-1 is more than an **interleukin** immunology today.

3: 113-9.

Oppenheim J, Kovacs J and Mastushenia K (1986).

There is more than **interleukin-1** immunology today.

45-56.

Oppenheim J, Ruscetti W and Fallynek C (1991).

Cytokines In: Sittes Dp and Ten AI (eds) basic and clinical immunology.

7th ed. California Lange Medical Publication, 78: 100.

Ota K, Kitano U and **Miyasaka** N (1989).

Clinical and pathophysiological aspects of dialysis-associated **amyloidosis**.

Nephrol Dial Transplant, 4 (suppl): 7-70.

Pangburn K and Muller-Eberhard J (1980).

Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.

J Exp Med, 152: 1102-14.

Pereira J, King J, Falagas E and Dinarello A (1994).

Interleukin-1 receptor antagonist: An index of dialysis. Induced **interleukin-1** production.

Nephron 67 (3): 358-61.

Petersen J, Moore R, Kaczmarek G, Singh B, Yeh I, Hamburger S and Kankam M (1991).

The effect of reprocessing cuprophane and polysulphone dialyzer on beta-2-Microglobulin removal from hemodialysis patients.

American Journal of kidney Diseases, 17 (2): 174-8.

Peterson A, Evrin E and Berggard I (1969).

Diffrentiation of glomerular, tubular, and removal protenuria. Determination of urinary excretion of **B2-Microglobulin**, albumin and total protein.

J Clin Investig, 48: 1189-98.

Philip R and Epstein B (1986).

Tumor necrosis factor as **immunodulator** and mediator of monocyte cytotoxicity induced by itself, gamma interferon and **interleukin-1**.

Nature, 323: 86-9.

Phillipe M, William J and Raymond M (1990).

Effect of dialysis membranes on beta **-2-Microglobulin** production and cellular expression kidney international.

Vol, 38: p.p 962-968.

Platanias C and Vogelzang J (1990).

Interleukin-1: Biology, pathoysiolgy and clinical prospects.

Am J Med, 89: 627-9.

Putz D, Barnas U, Luger A, Mayer G, Woloszczuk W and Graf H (1992).

Biocompatibility of high flux membranes.

International journal of Artificial Organs, 15 (8): 456-60.

Ramadori G, Sipe D, Dinarello A, Mizel B and Colten R (1985).

Pretranslation modulation of acute phase hepatic protein synthesis by murine recombinant **interleukin-1** and purified human **IL-1**.

J Exp Med, 162: 930-42.

Raska K, Raskova J, Shea M, Frankel M, Wood H, Lifter J, Ghobrial I, Eisinger R and Homer L (1983).

T-cell subsets and cellular immunity in end stage renal disease.

Am J Med, 75: 734-40.

Rubin L, Riggio R, Nachman I, Schwartz H, Miyata T and Stenzel H (1968).

Collagen materials in dialysis and implantation.

Trans Am Soc Artif Intern Organs, 14: 169.

Schardijn C and Statius Van Eps W (1987).

B2-Microglobulin: Its significance in the evaluation of renal function.

Kidney int, 32: 635-41.

Schindler R, **Linnenweber** S, Schulze M and **Oppermann** M (1993).

Gene expression of **interleukin-1** beta during hemodialysis.

kidney international, 43 (3): 712-21.

Schoel S, Janh B, Hug F Deppisch R, Ritz E and Hansch M (1993).

Stimulation of mononuclear cells by contact with cuprophane membranes: further increase of beta-2-Microglobulin synthesis by activated late complement component.

American journal of kidney diseases, 27 (4): 394-9.

Schwartz A, Keller F, Seyfert S, Poll W, Molzahn M and Distler A (1984).

Carpel tunnel syndrome: A major complication in long-term hemodialysis patients.

Clin Nephrol, 22: 133-7.

Seckinger P, Lowenthal W, Williamson K, Dayer M and Macdonald (1987).

A urine inhibitor of **interleukin-1** activity that blocks ligand binding.

J Immunol, 139: 1546-9.

Shaldon S, Deschod G, Branger B, Granolleras G, Baldamus A, Koch M, Lysaght J and Dinarello A (1985).

Haemodialysis hypotension, the **interleukin** hypothesis restated.

Proc Eur Dial Transplant Ass, 22: 229-43.

Shin J, Matsu O, Shinko S, Fujita Y, Inoue S, **Sakaai** R and **Nishioka** M (1980).

A study of haemodialysis leucopenia using various dialyzers.

J Dial, 4: 51.

Shuster J, Gold P and Poulik (1976).

B2-Microglobulin levels in cancerous and other disease states.

Clin Chim Acta, 67: 307-13.

Sims H and Miller L (1984).

B2-Microglobulin in laboratory diagnosis.

Lab Med, 15: 803-5.

Stenzel H, Rubin L, Yamayoshi W, Miyata T, Suzuki T, Sohde T and Nishizawa M (1971).

Optimization of collagen dialysis membranes.

Trans Am Soc Artif Intern Organs, 17: 293.

Swanson A, Tracy P, Katzmann A, Wilson M and Young S (1982).

B2-Microglobulin determination by radio immunoassay with monoclonal antibody.

Clin Chem, 28 (10): 2033-9.

Szepietowski T and Orlowski A (1991).

Interaction between blood and dialysis membranes [Review] [Polish].

Polimery W Medycynie, 21 (3-4): 3-13.

Tack F, Harrison A, Janatova J, Thomas L and Prahl W (1980).

Evidence for presence of an internal thiolester bond in third component of human complement.

Proc Natl Acad Sci USA, 77: 5764-8.

Talal N, Grey M and Zvaifler N (1975).

Elevated salivary and synovial fluid B2-Microglobulin in sjogren's syndrome and Rheumatoid arthritis.

Science, 187: 1196-8.

Tang E and Van Den Bergh W (1981).

The tubular Handling of B2-Microglobulin in sickle cell nephropathy.

Nephron, 29: 138-41.

Tetta C, Jeantet A, Caniussi G, Thea A, Crmol L, Martini F, Ragni R and VercelloneA (1984).

Direct interaction between polymorphonuclear neutrophils and cuprophane membranes in a plasma-free model of dialysis.

Proc Edta, 21: 150-5.

Thomas L, Janatova J, Gray R and Tack F (1982).

Third component of human complement: Localization of the internal thiolester bond.

Proc Natl Acad Sic USA, 79: 1054-8.

Toren M, **Goffinet** A and Kaplow S (1970).

Pulmonary bed sequestration of neutrpohils during haemodialysis.

Blood, 36: 337.

Toupance O, Lavaud S, Gillery P, Melin J and Chanard J (1987).

Extracellular fluid volume and B2-Microglobulin concentration under hemodialysis.

Nephrol Dial Transplant, 2: 449-50.

Tulkens M (1986).

Experimental studies on nephrotoxicity of aminoglycoside at low doses.

Am J Med, 80 (suppl 6B): 105-14.

Van Ypersele de strihour C, Honhom B, Vandenbroucke M, Huaux P, Noel H and Maldague B (1988).

Dialysis amyloidosis.

Adv Nephrol, 17: 404-22.

Vandersteen A (1986).

research or dialyzers with improved biocompatibility.

Clin Nephrol, 26: 539-42.

Vaziri D, Wang J, Cesario T, Yousefi S, Valenzuela R and Carandang G (1994).

Induction, transcription synthesis, and adsorption of **interleukin-1** by dialyzer membranes.

Journal of the American society of nephrology, 4 (11): 1884-9.

Vienken J and Harding M (1989).

Dialysis membranes and **B2-Microglobulin** : Interactions, limitations and perspectives.

Nephrol Dial Transplant, 4 (suppl): 27-31.

Vilcek J (1987).

Tumor necrosis factor and **interleukin-1** **Cytokines** with multiple overlapping biological activities.

Lab Invest, 86: 234-48.

Vincent C and Revillard P (1976).

Comparison of **radioimmunoassay** and **lymphototoxicity** inhibition technique for determination of **B2-Microglobulin**.

J **immunol** Methods, 10: 253-9.

Vincent C, Pozet N and Revillard J (1980).

Serum levels and urinary excretion of B2-microglobulin in patients under haemodialysis or after renal transplantation.

Acta **Clin Belg**, 35 (suppl 10): 31-9.

Vonhartzsch B, Can D, Kjellstrand M and Kerr S (1973).

Normal red cell survival in well dialyzed patients.

Trans Am Soc Artif Intern Organs, 19: 471.

Walker F, Lrndsay R, Sibbald W and Linton L (1984).

Changes in pulmonary vascular tone during early hemodialysis.

Trans Am Soc Artif Intern Organs, 30: 168-72.

Watson J and **Mochiznki** D (1980).

Interleukin-2 A class of T cell growth factor.

Immunol Rev, 51: 257-78.

Weir M (1988).

Aquired immunology in: Immunology student note. 6 th ed.

Edinburgh, London, New **york** Churchill living stone, 108-10.

Whicher T (1995).

Cytokines diagnostic aspect.

Scand J Clin Lab Invest, Vol (55) Supp(223).

Wibell L (1976).

Studies on **B2-Microglobulin** in patients and normal subjects.

Acta **Clin** Belg, 31; (suppl 8): 14-26.